Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The rules of ASCO state that the abstract and presentation should not report preliminary results before the close of Phase 1. Presenters can include all pre-clinical data and state things like the Phase 1 tests so far are in line with results from animal testing, but specific information and data about PK/PD and efficacy can't be included.

Kevetrin preliminary results can be PRed but only after permission from Dana Farber. We don't know when that will be. But, so far trail updates have included cohort completions and advancement, but no data at all except to generally say no dose limiting toxicities.

So, if any preliminary results are announced ahead of ASCO, then details will probably discussed during q&a and private meetings.